Dean Y. Li - Nov 17, 2021 Form 4/A - Amendment Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Nov 17, 2021
Transactions value $
-$384,962
Form type
4/A - Amendment
Date filed
12/9/2021, 08:17 PM
Date Of Original Report
Nov 19, 2021
Previous filing
Oct 5, 2021
Next filing
Dec 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$113K -5.63K -0.42% $20.04 1.34M Nov 17, 2021 By Dean Y. Li 2021 GRAT F1, F2, F3
transaction RXRX Class A Common Stock Sale -$272K -13.5K -1% $20.20 1.33M Nov 19, 2021 By Dean Y. Li 2021 GRAT F1, F3, F4
holding RXRX Class A Common Stock 597K Nov 17, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT.
F4 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.